Antigen News and Research

RSS

Factors predictive of sequential nucleos(t)ide analogue, IFN-α therapy response identified

Hepatitis B surface antigen and hepatitis B core-related antigen levels can predict long-term response to sequential nucleos(t)ide analogue and interferon-α therapy in patients with chronic hepatitis B virus infection, research indicates.

13 Mar 2015

Islet autoantibody levels predict progression to diabetes

Levels of insulin autoantibodies and insulinoma-associated protein 2 autoantibodies predict the onset of diabetes in young children with islet autoimmunity, show findings from the TEDDY study.

13 Mar 2015

HBV genotype C HBeAg seroconversion rate ‘negligible’

Patients with chronic hepatitis B virus genotype C infection who are positive for hepatitis B e antigen should not delay antiviral treatment in the hope of seroconversion, Korean researchers recommend.

13 Mar 2015

Penn researcher named a recipient of 2015 Paul Ehrlich and Ludwig Darmstaedter Prize

University of Pennsylvania cancer and HIV expert Carl June, MD, has been named one of two recipients of the 2015 Paul Ehrlich and Ludwig Darmstaedter Prize for his outstanding work in cancer immunotherapy. Since 1952, the Paul Ehrlich and Ludwig Darmstaedter Prize has been awarded to scientists who have made great advancements in the fields in which Paul Ehrlich worked, in particular immunology, cancer research, microbiology, and chemotherapy.

12 Mar 2015

Tetanus booster shot enhances effect of vaccine therapy for lethal brain tumors

An innovative approach using a tetanus booster to prime the immune system enhances the effect of a vaccine therapy for lethal brain tumors, dramatically improving patient survival, according to a study led by Duke Cancer Institute researchers.

12 Mar 2015

Researchers assess effectiveness of point of care tests for detecting Schistosomiasis infections

Researchers from the Cochrane Infectious Disease Group, hosted at LSTM, have conducted an independent review to assess how well point of care tests detect Schistosoma infections in people living in endemic regions.

12 Mar 2015

United Therapeutics announces FDA approval of dinutuximab for treatment of high-risk neuroblastoma

United Therapeutics Corporation announced today that the United States Food and Drug Administration has approved Unituxin (dinutuximab) Injection (formerly called ch14.18), in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy.

10 Mar 2015

New type of vaccine holds promise for prevention of genital herpes

Scientists at Albert Einstein College of Medicine of Yeshiva University have designed a new type of vaccine that could be the first-ever for preventing genital herpes--one of the most common sexually transmitted diseases, affecting some 500 million people worldwide.

9 Mar 2015

Nanobody Nano-85 holds promise for detection of noroviral RNA

Infection with highly contagious noroviruses, while not usually fatal, can lead to a slew of unpleasant symptoms such as excessive vomiting and diarrhea. Current treatment options are limited to rehydration of the patient. "Additionally, noroviruses come in a variety of constantly evolving strains.

9 Mar 2015

Key 'energy producing' protein plays a critical role in a good immune system

A good immune system relies on a key 'energy producing' protein in immune cells to develop immunity to vaccines and disease, an international team of scientists has found.

6 Mar 2015

Asterias begins enrollment for AST-OPC1 Phase 1/2a trial to treat complete cervical spinal cord injury

Asterias Biotherapeutics, Inc., a leading biotechnology company in the emerging field of regenerative medicine, announced today that Atlanta-based Shepherd Center, one of the nation's top rehabilitation hospitals for spinal cord injury and brain injury, has commenced enrollment for the Phase 1/2a clinical trial of AST-OPC1 (oligodendrocyte progenitor cells) in newly injured patients with sensory and motor complete cervical spinal cord injury (SCI).

5 Mar 2015

New antibody provides 100% protection against H5N1 influenza virus in animal models

Since 2003, the H5N1 influenza virus, more commonly known as the bird flu, has been responsible for the deaths of millions of chickens and ducks and has infected more than 650 people, leading to a 60 percent mortality rate for the latter. Luckily, this virus has yet to achieve human-to-human transmission, but a small number of mutations could change that, resulting in a pandemic.

4 Mar 2015

Texas Tech University professor receives CPRIT grants to study movement of tumor cells

Siva Vanapalli, an associate professor in the Department of Chemical Engineering, at Texas Tech University, recently received two grants from the Cancer Prevention and Research Institute of Texas to study the movement of tumor cells throughout the body and new methods of detecting cancer cells.

3 Mar 2015

Celimmune licenses anti-IL-15 monoclonal antibody from Amgen

Celimmune LLC, a clinical development-stage immunotherapy company focused on treating and preventing autoimmune diseases, announced today that it has licensed a Phase 2-stage, anti-IL-15 monoclonal antibody (AMG 714) from Amgen.

2 Mar 2015

TxCell invited to speak at largest US meeting for investors in emerging growth companies

In the presentation, Damian Marron will provide an overview of TxCell and its personalized T cell immunotherapy platform ASTrIA. Additional details will also be provided to institutional investors in one on one meetings at the conference.

27 Feb 2015

ABIVAX doses first patient in ABX203 Phase IIb/III trial for treatment of chronic hepatitis B

ABIVAX, a clinical stage biotech company developing and commercialising anti-viral compounds and human vaccines, today announced that it has dosed in New Zealand the first patient in a Phase IIb/III clinical trial of ABX203 which is taking place in several countries of the Asia-Pacific region.

26 Feb 2015

Researchers reveal how malaria parasite deploys genetic trickery to escape immune system attack

Up to one million people -- mainly pregnant woman and young children -- are killed each year by the Plasmodium falciparum parasite, which causes the most devastating form of human malaria.

26 Feb 2015

Virginia Tech biochemists identify potential drug target against sleeping sickness

Virginia Tech biochemists are trying to deliver a stern wake-up call to the parasite that causes sleeping sickness.

24 Feb 2015

New Duke-NUS-led study identifies super-potent antibody that can neutralize dengue virus

A new Duke-NUS-led study has identified a super-potent antibody which requires a minute amount to neutralize the dengue virus.

21 Feb 2015

Proximity Ligation Assay helps detect effectiveness of cancer vaccines

Cancer vaccines are designed to turn the body's own immune system specifically against tumor cells. Particularly promising are vaccines that are directed against so-called neoantigens: These are proteins that have undergone a genetic mutation in tumor cells and, therefore, differ from their counterparts in healthy cells.

20 Feb 2015

Antigen News and Research

Factors predictive of sequential nucleos(t)ide analogue, IFN-α therapy response identified

Islet autoantibody levels predict progression to diabetes

HBV genotype C HBeAg seroconversion rate ‘negligible’

Penn researcher named a recipient of 2015 Paul Ehrlich and Ludwig Darmstaedter Prize

Tetanus booster shot enhances effect of vaccine therapy for lethal brain tumors

Researchers assess effectiveness of point of care tests for detecting Schistosomiasis infections

United Therapeutics announces FDA approval of dinutuximab for treatment of high-risk neuroblastoma

New type of vaccine holds promise for prevention of genital herpes

Nanobody Nano-85 holds promise for detection of noroviral RNA

Key 'energy producing' protein plays a critical role in a good immune system

Asterias begins enrollment for AST-OPC1 Phase 1/2a trial to treat complete cervical spinal cord injury

New antibody provides 100% protection against H5N1 influenza virus in animal models

Texas Tech University professor receives CPRIT grants to study movement of tumor cells

Celimmune licenses anti-IL-15 monoclonal antibody from Amgen

TxCell invited to speak at largest US meeting for investors in emerging growth companies

ABIVAX doses first patient in ABX203 Phase IIb/III trial for treatment of chronic hepatitis B

Researchers reveal how malaria parasite deploys genetic trickery to escape immune system attack

Virginia Tech biochemists identify potential drug target against sleeping sickness

New Duke-NUS-led study identifies super-potent antibody that can neutralize dengue virus

Proximity Ligation Assay helps detect effectiveness of cancer vaccines

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News